| __timestamp | Amicus Therapeutics, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 14993000000 |
| Thursday, January 1, 2015 | 47269000 | 14247000000 |
| Friday, January 1, 2016 | 71151000 | 14192000000 |
| Sunday, January 1, 2017 | 88671000 | 14997000000 |
| Monday, January 1, 2018 | 127200000 | 16471000000 |
| Tuesday, January 1, 2019 | 169861000 | 14369000000 |
| Wednesday, January 1, 2020 | 156407000 | 14197000000 |
| Friday, January 1, 2021 | 192710000 | 14886000000 |
| Saturday, January 1, 2022 | 213041000 | 14253000000 |
| Sunday, January 1, 2023 | 275270000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Amicus Therapeutics, Inc. over the past decade. From 2014 to 2023, Novartis AG, a global healthcare giant, consistently reported SG&A expenses averaging around $14.5 billion annually. However, a notable decline of approximately 17% was observed from 2022 to 2023, reflecting strategic cost-cutting measures.
Conversely, Amicus Therapeutics, a smaller biotech firm, exhibited a steady increase in SG&A expenses, growing over 1,200% from 2014 to 2023. This surge underscores the company's aggressive expansion and investment in market presence. The contrasting trends between these two companies highlight diverse strategies in managing operational costs, offering valuable insights for stakeholders and investors navigating the pharmaceutical sector.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Amicus Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.